CONFIDENTIAL Amendment #2 to the Letter of Agreement between SmithKline Beecham Corporation and Quest Diagnostics Incorporated

EX-10.6 7 c54355_ex10-6.htm c54355_ex10-6.htm -- Converted by SEC Publisher, created by BCL Technologies Inc., for SEC Filing

Exhibit 10.6

CONFIDENTIAL

Amendment #2 to the
Letter of Agreement between
SmithKline Beecham Corporation and
Quest Diagnostics Incorporated

1.     

The purpose of this Amendment #2 to the Letter of Agreement effective January 1, 2008 between SmithKline Beecham Corporation d/b/a GlaxoSmithKline and Quest Diagnostics Incorporated (hereinafter the “LOA”) is to extend the term referenced in section 2 of the LOA to the earlier of (i) June 30, 2008, or (ii) the full execution of a new comprehensive Global Clinical Trials Agreement.

 
2.     

All other terms and conditions of the LOA shall remain in full force and effect.

 
3.     

The parties hereto agree to this Amendment #2 to the LOA by their authorized signatures below.

 
SMITHKLINE BEECHAM CORPORATION   QUEST DIAGNOSTICS INCORPORATED  
 
 
/s/ Paula M. Russella   /s/ Daniel P. Megronigle  
Paula M. Russella   Daniel P. Megronigle  
Sourcing Group Manager   Executive Director, Sales & Marketing  
 
May 21, 2008   May 15, 2008  
Date   Date